Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

495 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.
Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, Byrd J, Sokol L, Lawrence N, Pireddu R, Dewald G, Williams A, Maciejewski J, List A. Wei S, et al. Among authors: list a. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12974-9. doi: 10.1073/pnas.0811267106. Epub 2009 May 26. Proc Natl Acad Sci U S A. 2009. PMID: 19470455 Free PMC article.
Efficacy of lenalidomide in myelodysplastic syndromes.
List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB. List A, et al. N Engl J Med. 2005 Feb 10;352(6):549-57. doi: 10.1056/NEJMoa041668. N Engl J Med. 2005. PMID: 15703420 Free article. Clinical Trial.
Developmental therapeutics for myelodysplastic syndromes.
Naing A, Sokol L, List AF. Naing A, et al. Among authors: list af. J Natl Compr Canc Netw. 2006 Jan;4(1):78-82. doi: 10.6004/jnccn.2006.0008. J Natl Compr Canc Netw. 2006. PMID: 16403406 Review.
New agents in the treatment of MDS.
List AF. List AF. Clin Adv Hematol Oncol. 2005 Nov;3(11):832-4. Clin Adv Hematol Oncol. 2005. PMID: 16491623 No abstract available.
Lenalidomide: an immunomodulatory drug.
Crane E, List A. Crane E, et al. Among authors: list a. Future Oncol. 2005 Oct;1(5):575-83. doi: 10.2217/14796694.1.5.575. Future Oncol. 2005. PMID: 16556034 Review.
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R; Myelodysplastic Syndrome-003 Study Investigators. List A, et al. N Engl J Med. 2006 Oct 5;355(14):1456-65. doi: 10.1056/NEJMoa061292. N Engl J Med. 2006. PMID: 17021321 Free article. Clinical Trial.
495 results